宫内暴露于17α-羟孕酮己酸酯与子代癌症风险
基于儿童健康与发展研究队列的超过18,000对母婴,评估宫内暴露于17α-羟孕酮己酸酯与子代癌症风险的关联。随访至2019年,1008例子代确诊癌症;孕早期暴露与任何癌症风险升高相关(调整HR 2.57,95%CI 1.59-4.15),且风险随注射次数增加。结论认为鉴于子代癌症的潜在关联,孕早期使用17α-羟孕酮己酸酯需谨慎。
要点
- 孕早期暴露于17α-羟孕酮己酸酯与子代任何癌症风险升高相关。
- 风险随注射次数增加:1-2次调整HR 1.80,≥3次调整HR 3.07。
- 孕中晚期暴露仅男性子代风险升高(调整HR 2.59),女性子代无显著关联。
核心结论
- 鉴于子代癌症的潜在关联,孕早期使用17α-羟孕酮己酸酯需谨慎。
研究设计与样本
- 儿童健康与发展研究为基于人群的队列,纳入1959至1966年间在Kaiser Foundation Health Plan(加州奥克兰)接受产前保健的超过18,000对母婴。
- 从母亲病历摘录孕前6个月至分娩的临床信息,识别孕期17α-羟孕酮己酸酯注射次数和时间。
- 通过链接加州癌症登记处确定至2019年子代发生的癌症,采用Cox比例风险模型估计调整风险比及95%置信区间。
主要发现
- 随访730,817人年期间,共1008例子代确诊癌症;约1.0%的子代(n=234)在宫内暴露于17α-羟孕酮己酸酯。
- 孕早期暴露与任何癌症风险升高相关(调整HR 2.57;95%CI 1.59-4.15),且风险随注射次数增加:1-2次调整HR 1.80(95%CI 1.12-2.90),≥3次调整HR 3.07(95%CI 1.34-7.05)。
- 孕中晚期暴露对男性子代增加额外风险(调整HR 2.59;95%CI 1.07-6.28),对女性子代无显著关联(调整HR 0.30;95%CI 0.04-1.11)。
- 孕早期首次暴露的子代中,结直肠癌(调整HR 5.51;95%CI 1.73-17.59)、前列腺癌(调整HR 5.10;95%CI 1.24-21.00)和儿童脑癌(调整HR 34.72;95%CI 7.29-164.33)风险高于未暴露子代。
关键数值与推荐
- 孕早期暴露与任何癌症风险升高相关(调整HR 2.57;95%CI 1.59-4.15)。
- 1-2次注射调整HR 1.80(95%CI 1.12-2.90),≥3次注射调整HR 3.07(95%CI 1.34-7.05)。
- 孕中晚期暴露男性子代调整HR 2.59(95%CI 1.07-6.28),女性子代调整HR 0.30(95%CI 0.04-1.11)。
- 孕早期首次暴露子代结直肠癌调整HR 5.51(95%CI 1.73-17.59),前列腺癌调整HR 5.10(95%CI 1.24-21.00),儿童脑癌调整HR 34.72(95%CI 7.29-164.33)。
临床怎么用
- 作者认为鉴于子代癌症的潜在关联,孕早期使用17α-羟孕酮己酸酯需谨慎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 17α-hydroxyprogesterone caproate is a synthetic progestogen initially approved in the 1950s to treat gynecologic and obstetrical conditions. Despite continued concerns about safety and short-term efficacy regarding the use of 17α-hydroxyprogesterone caproate for the prevention of preterm birth in pregnant women, little is known about the long-term effects of 17α-hydroxyprogesterone caproate on the health of the offsprings. OBJECTIVE: To examine the association between in utero exposure to 17α-hydroxyprogesterone caproate and the risk of cancer in the offspring. STUDY DESIGN: The Child Health and Development Studies was a population-based cohort of >18,000 mother-child dyads receiving prenatal care in the Kaiser Foundation Health Plan (Oakland, CA) between 1959 and 1966. Clinical information was abstracted from the mothers' medical records beginning 6 months before pregnancy through delivery. We identified the number and timing of 17α-hydroxyprogesterone caproate injections during pregnancy. Incident cancers diagnosed in the offspring were ascertained through 2019 by linkage to the California Cancer Registry. We used the Cox proportional hazard models to estimate the adjusted hazard ratios and their 95% confidence intervals, with the follow-up time accrued from the date of birth through the date of cancer diagnosis, death, or last contact. RESULTS: A total of 1008 offspring were diagnosed with cancer over 730,817 person-years of follow-up. Approximately 1.0% of the offspring (n=234) were exposed in utero to 17α-hydroxyprogesterone caproate. Exposure in the first trimester was associated with an increased risk of any cancer (adjusted hazard ratio, 2.57; 95% confidence interval, 1.59-4.15), and the risk increased with the number of injections (1-2 injections: adjusted hazard ratio, 1.80; 95% confidence interval, 1.12-2.90; ≥3 injections: adjusted hazard ratio, 3.07; 95% confidence interval, 1.34-7.05). Exposure in the second or third trimester conferred an additional risk for the male (adjusted hazard ratio, 2.59; 95% confidence interval, 1.07-6.28) but not for the female (adjusted hazard ratio, 0.30; 95% confidence interval, 0.04-1.11) offspring. The risk of colorectal (adjusted hazard ratio, 5.51; 95% confidence interval, 1.73-17.59), prostate (adjusted hazard ratio, 5.10; 95% confidence interval, 1.24-21.00), and pediatric brain (adjusted hazard ratio, 34.72; 95% confidence interval, 7.29-164.33) cancer was higher in the offspring first exposed to 17α-hydroxyprogesterone caproate in the first trimester than the offspring not exposed. CONCLUSION: Caution using 17α-hydroxyprogesterone caproate in early pregnancy is warranted, given the possible link with cancer in the offspring.
引用
- Murphy CC, Cirillo PM, Krigbaum NY, et al. In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring. Am J Obstet Gynecol. 2021. PMID: 34767803. doi:10.1016/j.ajog.2021.10.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。